Thermo-Fisher BRAHMS test falls short of NICE "impact evidence" needs
This article was originally published in Clinica
Executive Summary
A highly promising innovative technology, Thermo-Fisher’s BRAHMS copeptin assay test for ruling out a suspected heart attack, has fallen short of full support for its use in the UK’s NHS, as a result of inadequate “clinical practice impact” evidence.